NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration

Stock Information for NervGen Pharma Corp

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NervGen Pharma Corp

CSE Bulletin: Fundamental Change - 12 Exploration Inc. (TWLV)
TransCanna Receives Approval To Begin Trading On The Frankfurt Stock Exchange
TransCanna's Affiliate TCM Distribution, Inc. Receives State of California Temporary Distributor License
Broadcom Inc. Completes Acquisition of CA Technologies
Research Report Identifies CA, Altra Industrial Motion, Forward Air, Franklin Street Properties, CME Group, and C.H. Robinson Worldwide with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
Keysight Technologies Set to Join S&P 500; Ligand Pharmaceuticals to Join S&P MidCap 400; Marcus & Millichap and Arcosa to Join S&P SmallCap 600
CA Technologies Updates Mainframe Solutions, Promoting an Open and Intelligent Platform for Hybrid Environments
NXP Semiconductors N.V. to Join the NASDAQ-100 Index Beginning November 5, 2018

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.